Global Medical & Evidence Strategy Lead: Bemdaneprocel, Parkinson's Disease

Global Medical & Evidence Strategy Lead: Bemdaneprocel, Parkinson's Disease At Bayer we’re visionaries, driven to solve the world’s toughest challenges and striving for a world where ‘Health for all Hunger for none’ is no longer a dream, but a real possibility. We’re doing it with energy, curiosity and sheer dedication, always learning from unique perspectives of those around us, expanding our thinking, growing our capabilities and redefining ‘impossible’. There are so many reasons to join us. If you’re hungry to build a varied and meaningful career in a community of brilliant and diverse minds to make a real difference, there’s only one choice. Bayer is committed to delivering Health for All by advancing a portfolio of innovative treatments. The company has the passion and determination to develop and commercialize medicines that help improve patients’ lives. To position the company for the future, Bayer has significantly invested in new fields of R&D. One major area of innovation has been Cell Therapy & Gene Therapy (CGT), where we have driven rapid advances via the acquisition of two leading companies in this space, AskBio and BlueRock. With this investment, Bayer has rapidly built a broad pipeline of assets across a multitude of disease areas. Our assets at the forefront of this pipeline have the potential to transform care for patients with Parkinson’s Disease (PD). Bemdaneprocel (out of BlueRock) is an experimental cell therapy that has been granted both Fast Track Designation and the Regenerative Medicine Advanced Therapy (RMAT) designation by the US Food & Drug Administration (FDA). The Phase 1 manuscript from this program was highlighted on the May 22, 2025 cover of Nature, and a Phase 3 registrational study is now ongoing. Successful commercialization of this asset provides an exciting challenge as we enter this new and important therapeutic area. Cell therapy technologies bring additional complexities with advanced science, sophisticated delivery and distribution models, as well as unique value propositions. Bemdaneprocel promises to be the first successful cell therapy for Parkinson’s disease, with the potential to transformatively impact many lives. This is a high-impact, high-visibility role that requires an entrepreneurial mindset and a desire to challenge conventional approaches and deliver medical & evidence strategy and leadership for commercial launch. This is a key position on the Global Product Leadership Team. The GME Strategy Lead is responsible for the global medical and evidence strategy for this pioneering cell therapy in Parkinson’s Disease, partnering with BlueRock colleagues, internal capability clusters, worldwide markets, and key external stakeholders. Responsibilities As a key member of the Bemdaneprocel Product Team (PT), the incumbent will work in partnership to co‑create the product strategy to maximize asset value and patient impact; As Visionary, Architect, Catalyst, and Coach (VACC), the incumbent provides leadership to define integrated medical and evidence outcomes for optimized asset differentiation and positioning to ensure launch readiness; Leads the development of integrated medical affairs and evidence generation strategy, providing medical and evidence input, market insights, critical thinking, and stakeholder perspectives to continuously evolve and calibrate asset strategy and strategic collaborations; Leads the Bemdaneprocel PT medical and evidence sub‑teams and works in partnership with relevant colleagues to define and shape the outcomes and missions required to enable successful implementation of the PT integrated medical and evidence plan, including collaboration and input from global evidence leads, medical leads, regional/local medical and evidence colleagues; Ensures seamless communication across the Bendaneprocel PT, related customer teams, and all medical and evidence stakeholders involved with the asset, promoting transparency, creativity, and a solution‑oriented mindset; Translates business challenges into evidence‑ and insight‑backed solutions, utilizing traditional and innovative methods, inclusive of primary and observational research approaches; Advances newly initiated natural history study in Parkinson’s disease, conducted in collaboration with Bayer, BlueRock, and AskBio; Contributes to the analysis and interpretation of results from Clinical Development studies as well as prospective and secondary observational research, including GME‑sponsored studies, ISCSs, and IIRs, both internally and externally; Establishes meaningful and sustainable relationships with global/regional Thought Leaders; Oversees planning and management of key local and global scientific symposia. Required Qualifications Medical doctor or equivalent; Deep experience in Clinical Development, Medical Affairs and/or Evidence Generation function of a global healthcare organization or equivalent at regional or country level; Indication, disease, and therapeutic area knowledge in both existing and emerging treatments for Parkinson’s Disease and/or relevant neurologic diseases as well as thorough understanding of drug development process over different stages; Adept strategic and global mindset with a 360° understanding of business/financial domains and medical and evidence (including Real World Evidence) functions; ability to anticipate future needs and opportunities through both analytic and creative mindsets; Excellent internal and external senior stakeholder management and relationship‑building skills; ability to build trustful and long‑lasting partnerships; High learning agility, adapting to changes in product indications and proactively upskilling and expanding knowledge in relevant domains; Successful track record in effectively managing risk and compliance issues as well as high sense of accountability; Strong internal sense of accountability and perpetual self‑improvement; Demonstrates and showcases VACC leadership; Fluent in English; verbally and in writing, anchored in proven effective communication skills to communicate business strategies and capabilities internally and externally. Preferred Qualifications Specialty/fellowship training in Neurology/Movement Disorders or Neurosurgery highly preferred; Launch experience is highly preferred; Experience in cell therapy preferred. Salary & Benefits Employees can expect to be paid a salary of between $299,695 to $449,542. Additional compensation may include a bonus or commission (if relevant). Additional benefits include health care, vision, dental, retirement, PTO, sick leave, etc. This salary range is merely an estimate and may vary based on an applicant’s location, market data/ranges, an applicant’s skills and prior relevant experience, certain degrees and certifications, and other relevant factors. This posting will be available for application until at least: 9/23/2025. Application Bayer offers a wide variety of competitive compensation and benefits programs. If you meet the requirements of this unique opportunity, and want to impact our mission “Science for a better life”, we encourage you to apply now. Be part of something bigger. Be you. Be Bayer. To all recruitment agencies: Bayer does not accept unsolicited third‑party resumes. Equal Opportunity & Accommodations Bayer is an Equal Opportunity Employer/Disabled/Veterans. Bayer is committed to providing access and reasonable accommodations in its application process for individuals with disabilities and encourages applicants with disabilities to request any needed accommodation(s) using the contact information below. Bayer is an E‑Verify Employer. Location United States : Massachusetts : Cambridge Division Pharmaceuticals Reference Code 852895 Contact Email: View email address on click.appcast.io Seniority Level Director Employment Type Full‑time Job Function Health Care Provider Industries Chemical Manufacturing, Pharmaceutical Manufacturing, and Biotechnology Research #J-18808-Ljbffr Bayer